SI-BONE (SIBN) Stock Price, News & Analysis

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SIBN shares.
View SIBN analyst ratings or view top-rated stocks.

5 brokerages have issued 1-year price objectives for SI-BONE's stock. Their SIBN share price targets range from $24.00 to $33.00. On average, they predict the company's share price to reach $26.67 in the next year. This suggests a possible upside of 74.3% from the stock's current price.
View analysts price targets for SIBN or view top-rated stocks among Wall Street analysts.

SI-BONE's stock was trading at $20.99 on January 1st, 2024. Since then, SIBN stock has decreased by 27.1% and is now trading at $15.30.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our SIBN earnings forecast.

SI-BONE will be holding an earnings conference call on Monday, May 6th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

SI-BONE, Inc. (NASDAQ:SIBN) issued its quarterly earnings results on Monday, February, 26th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.02. The company had revenue of $38.86 million for the quarter, compared to the consensus estimate of $38.60 million. SI-BONE had a negative trailing twelve-month return on equity of 28.22% and a negative net margin of 31.20%.

SI-BONE issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $162.0 million-$165.0 million, compared to the consensus revenue estimate of $159.1 million.

10 employees have rated SI-BONE Chief Executive Officer Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among the company's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), RTX (RTX), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO) and CSX (CSX).

SI-BONE (SIBN) raised $84 million in an IPO on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

SI-BONE's stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.41%) and Diversified Trust Co (0.05%). Insiders that own company stock include Anshul Maheshwari, Anthony J Recupero, Anthony J Recupero, Gregory K Hinckley, Jeffrey W Dunn, Jeffrey W Dunn, Jeryl L Hilleman, Jeryl L Hilleman, John Gordon Freund, Laura Francis, Michael A Pisetsky, Michael A Pisetsky, Mika Nishimura and Timothy E Davis Jr.
View institutional ownership trends.

Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.